Allogene Therapeutics Reports Departure Of CFO Eric T. Schmidt
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics announced the departure of CFO Eric T. Schmidt. The company has started searching for a replacement, and Schmidt will remain with the company until August 2, 2023, to support Q2 financial reporting and ensure a smooth transition.
June 14, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Allogene Therapeutics' CFO Eric T. Schmidt is leaving the company, with a search for a replacement underway. Schmidt will stay until August 2, 2023, to support Q2 financial reporting.
The departure of a CFO can create uncertainty and potential short-term negative impact on the stock price. Investors may be concerned about the company's financial stability and the ability to find a suitable replacement. However, Schmidt's continued presence until August 2, 2023, for Q2 financial reporting may mitigate some of the concerns.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100